KR20150035521A - 암의 시험관내 진단 및 추적 방법 - Google Patents

암의 시험관내 진단 및 추적 방법 Download PDF

Info

Publication number
KR20150035521A
KR20150035521A KR20147030813A KR20147030813A KR20150035521A KR 20150035521 A KR20150035521 A KR 20150035521A KR 20147030813 A KR20147030813 A KR 20147030813A KR 20147030813 A KR20147030813 A KR 20147030813A KR 20150035521 A KR20150035521 A KR 20150035521A
Authority
KR
South Korea
Prior art keywords
cells
tumor
treg
ratio
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR20147030813A
Other languages
English (en)
Korean (ko)
Inventor
지리나 바르툰코바
라덱 스피섹
Original Assignee
소티오 에이.에스.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 소티오 에이.에스. filed Critical 소티오 에이.에스.
Publication of KR20150035521A publication Critical patent/KR20150035521A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G01N33/4915—Blood using flow cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57545—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the ovaries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/7051—T-cell receptor (TcR)-CD3 complex
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70514—CD4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70517—CD8
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Ecology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
KR20147030813A 2012-07-02 2013-06-27 암의 시험관내 진단 및 추적 방법 Withdrawn KR20150035521A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP20120174539 EP2682750A1 (en) 2012-07-02 2012-07-02 In vitro method for the diagnosis and surveillance of cancer
EP12174539.2 2012-07-02
US201261672941P 2012-07-18 2012-07-18
US61/672,941 2012-07-18
PCT/EP2013/063448 WO2014005909A1 (en) 2012-07-02 2013-06-27 In vitro method for the diagnosis and surveillance of cancer

Publications (1)

Publication Number Publication Date
KR20150035521A true KR20150035521A (ko) 2015-04-06

Family

ID=46397089

Family Applications (1)

Application Number Title Priority Date Filing Date
KR20147030813A Withdrawn KR20150035521A (ko) 2012-07-02 2013-06-27 암의 시험관내 진단 및 추적 방법

Country Status (18)

Country Link
US (1) US20150337384A1 (https=)
EP (2) EP2682750A1 (https=)
JP (1) JP2015526709A (https=)
KR (1) KR20150035521A (https=)
CN (1) CN104364656A (https=)
AU (1) AU2013286134A1 (https=)
BR (1) BR112014026661A2 (https=)
CA (1) CA2872668A1 (https=)
CL (1) CL2014002975A1 (https=)
EA (1) EA201500080A1 (https=)
HK (1) HK1202618A1 (https=)
IL (1) IL236197A0 (https=)
IN (1) IN2015DN00678A (https=)
MX (1) MX2014013079A (https=)
PH (1) PH12014502436A1 (https=)
SG (1) SG11201406581UA (https=)
WO (1) WO2014005909A1 (https=)
ZA (1) ZA201409298B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2514591A (en) * 2013-05-30 2014-12-03 Mologen Ag Predictive biomarker for cancer therapy
CA2940115C (en) 2014-02-24 2023-03-14 Ventana Medical Systems, Inc. Methods, kits, and systems for scoring the immune response to cancer by simultaneous detection of cd3, cd8, cd20 and foxp3
CA2942721A1 (en) * 2014-03-14 2015-09-17 Czerniecki, Brian J. Methods for monitoring cd4+ t-helper type 1 response in cancer and immune restoration
US20160266125A1 (en) * 2015-03-12 2016-09-15 John Wayne Cancer Institute Methods of treating and predicting progression of cancer based on t cell subsets
JP2018519295A (ja) * 2015-06-22 2018-07-19 プレジデント アンド フェローズ オブ ハーバード カレッジ 粘膜固有層調節性ｔ細胞の誘導
JP6100867B1 (ja) * 2015-11-06 2017-03-22 振武 曽 免疫状態の分析のための検査方法
CN106932576A (zh) * 2017-03-22 2017-07-07 山东大学深圳研究院 一种人调节性t细胞的免疫抑制功能的检测方法
EP4184169A1 (en) * 2017-05-19 2023-05-24 Royal Melbourne Institute of Technology Predicting responders to cyclophosphamide therapy
TWI793151B (zh) 2017-08-23 2023-02-21 瑞士商諾華公司 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途
CN108508196B (zh) * 2018-04-13 2020-10-27 何韶衡 一种检测人调节性t细胞亚型的试剂盒及检测方法
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
BR122022012697B1 (pt) 2018-07-10 2023-04-04 Novartis Ag Usos de derivados de 3-(5-hidróxi-1-oxoisoindolin-2-il)piperidina-2,6- diona, e kit
CN112740042B (zh) 2018-09-20 2025-05-23 文塔纳医疗系统公司 基于大小门控以分析流式细胞术数据

Also Published As

Publication number Publication date
WO2014005909A1 (en) 2014-01-09
CN104364656A (zh) 2015-02-18
JP2015526709A (ja) 2015-09-10
SG11201406581UA (en) 2015-01-29
EP2867677A1 (en) 2015-05-06
IL236197A0 (en) 2015-01-29
EA201500080A1 (ru) 2015-06-30
EP2682750A1 (en) 2014-01-08
AU2013286134A1 (en) 2015-01-22
PH12014502436A1 (en) 2015-01-12
CA2872668A1 (en) 2014-01-09
ZA201409298B (en) 2015-12-23
MX2014013079A (es) 2014-12-08
HK1202618A1 (en) 2015-10-02
IN2015DN00678A (https=) 2015-06-26
BR112014026661A2 (pt) 2017-06-27
CL2014002975A1 (es) 2015-04-24
US20150337384A1 (en) 2015-11-26

Similar Documents

Publication Publication Date Title
KR20150035521A (ko) 암의 시험관내 진단 및 추적 방법
Brockmann et al. Molecular and functional heterogeneity of IL-10-producing CD4+ T cells
Vujanovic et al. CD56dim CD16− natural killer cell profiling in melanoma patients receiving a cancer vaccine and interferon-α
Ma et al. CCL2/CCR2-dependent recruitment of functional antigen-presenting cells into tumors upon chemotherapy
JP2020073924A (ja) がん免疫療法の臨床効果を予測する免疫学的バイオマーカー
Heid et al. FOXP3+ CD25− tumor cells with regulatory function in Sezary syndrome
US11096965B2 (en) Compositions and methods related to polycytotoxic T cells
CN116583537A (zh) 与对过继细胞疗法的应答相关的t细胞表型
Kryczek et al. Inflammatory regulatory T cells in the microenvironments of ulcerative colitis and colon carcinoma
Lattanzi et al. iNKT cell-neutrophil crosstalk promotes colorectal cancer pathogenesis
Kim et al. Multi-omics segregate different transcriptomic impacts of anti-IL-17A blockade on type 17 T-cells and regulatory immune cells in psoriasis skin
Harris et al. TCF-1 regulates NKG2D expression on CD8 T cells during anti-tumor responses
JP6846408B2 (ja) 自己免疫疾患または状態の検出のためのインビトロ方法
de Aguiar et al. Malignant and tuberculous pleural effusions: immunophenotypic cellular characterization
Jin et al. Stat5−/− CD4+ T cells elicit anti-melanoma effect by CD4+ T cell remolding and Notch1 activation
US20240066061A1 (en) A cxcr3+ cell or cell preparation for use in cancer treatment
Reinartz et al. Impact of AIM2 on HNSCC Development
KR20230062834A (ko) 암 치료에 대한 반응을 예측하기 위한 바이오마커
Sirc et al. Functionally characterizing the renal cell carcinoma tumor immune microenvironment via patient-derived ex vivo models
WO2016182944A1 (en) Cell culture systems for producing il-33 induced t9 cells and methods of using the cells
Jainarayanan et al. 173P Pseudotime dynamics in pancreatic ductal adenocarcinoma reveal different mechanisms of hindrance in immunity through bifurcation of regulatory and cytotoxic T-cell differentiation
He et al. Macrophages as Key Mediators of Trp-1-Specific CD4+ T Cell Therapy for Murine Melanoma
Djordjevic Role of bacteria-reactive T lymphocytes in immune responses against human colorectal cancer
Alcalde Deciphering the melanoma pre-metastatic niche at the single cell level
EP3964835A1 (en) Marker for diagnosing colorectal cancer and method for providing information required for diagnosis of colorectal cancer

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PC1203 Withdrawal of no request for examination

St.27 status event code: N-1-6-B10-B12-nap-PC1203

WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid
P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000